Literature DB >> 10207551

New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected.

O O Aalen1, V T Farewell, D De Angelis, N E Day, O N Gill.   

Abstract

BACKGROUND: A marked decline in the number of reported AIDS cases has been observed in the United Kingdom, as in many industrialized countries, in 1996 and 1997. In England and Wales, a large reduction in AIDS cases has been recorded among homosexual and bisexual men.
OBJECTIVES: To investigate, using data from the homosexuals and bisexuals in England and Wales as an example, possible explanations for the above decline such as the effects of new anti-retroviral therapies, or a decrease in the incidence of HIV in recent years.
METHODS: A multistage model of HIV infection, HIV diagnosis, treatment and of AIDS diagnosis has been used to represent the pattern of HIV and AIDS incidence in homosexual and bisexual men in England and Wales up to the end of 1995. Scenarios for the post-1995 period were examined under different assumptions about changes in HIV incidence in recent years and treatment uptake and efficacy.
RESULTS: The fall in the incidence of AIDS is unlikely to be the result of a reduction in HIV transmission during the 1990s. The most plausible explanation for this fall is the effect of new, more effective, anti-retroviral therapies. As a consequence, the number of individuals on treatment is likely to increase by 50 to 100% compared with the pre-1996 levels by the year 2001. Also, if the effect of the new therapies has a limited duration, or the use of such therapies is not well tolerated, the incidence of AIDS will rise again in the near future.
CONCLUSIONS: These findings indicate that a substantial workload increase is under way for the healthcare system, and reiterate the need for measures to reduce HIV transmission as a means of bringing about a sustainable change in the incidence of AIDS.

Entities:  

Mesh:

Year:  1999        PMID: 10207551     DOI: 10.1097/00002030-199901140-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Temporal trends in incidence of primary brain tumors in the United States, 1985-1999.

Authors:  Sara Hoffman; Jennifer M Propp; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

4.  Short-term physical and emotional health outcomes of public sector ART in the Free State province of South Africa.

Authors:  Edwin Wouters; Herman Meulemans; H C J Van Rensburg; J C Heunis; Dimitri Mortelmans
Journal:  Qual Life Res       Date:  2007-11       Impact factor: 4.147

Review 5.  HIV in gay and bisexual men in the United Kingdom: 25 years of public health surveillance.

Authors:  S Dougan; B G Evans; N Macdonald; D J Goldberg; O N Gill; K A Fenton; J Elford
Journal:  Epidemiol Infect       Date:  2007-07-30       Impact factor: 2.451

6.  The epidemiological impact of antiretroviral use predicted by mathematical models: a review.

Authors:  Rebecca F Baggaley; Neil M Ferguson; Geoff P Garnett
Journal:  Emerg Themes Epidemiol       Date:  2005-09-10

7.  Primary Central Nervous System Lymphoma: A Case of Solitary Brain Lesion.

Authors:  Halimat Lawal; Nya Anwanane; Anas Atrash
Journal:  Cureus       Date:  2021-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.